| Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis. | 2022 | Intestinal Research |
| Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease: systematic review and network meta-analysis of randomized controlled trials. | 2022 | Inflammatory Bowel Diseases |
| Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. | 2022 | BMC Gastroenterology |
| The effect of pregnancy and inflammatory bowel disease on the pharmacokinetics of drugs related to inflammatory bowel disease—a systematic literature review. | 2022 | Pharmaceutics |
| Systematic review and network meta-analysis: comparative efficacy and safety of biosimilars, biologics and JAK1 inhibitors for active Crohn disease. | 2021 | Frontiers in Pharmacology |
| Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. | 2021 | Expert Review of Gastroenterology & Hepatology |
| Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis. | 2021 | Digestive and Liver Disease |
| Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. | 2020 | Clinical Gastroenterology and Hepatology |
| Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. | 2020 | Clinical Gastroenterology and Hepatology |
| Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. | 2019 | Scandinavian Journal of Gastroenterology |
| Systematic review with meta‐analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. | 2019 | Alimentary Pharmacology & Therapeutics |
| Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review. | 2019 | Journal of Crohn’s and Colitis |
| Safety of vedolizumab in liver transplant recipients: a systematic review. | 2019 | United European Gastroenterology Journal |
| Systematic review and meta-analysis: vedolizumab and postoperative complications in inflammatory bowel disease. | 2018 | Inflammatory Bowel Diseases |
| Primary non-response to tumor necrosis factor antagonists is associated with Inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. | 2018 | Journal of Crohn's and Colitis |
| Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. | 2018 | Cochrane Database of Systematic Reviews |
| Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease. | 2018 | Journal of Crohn's and Colitis |
| Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis. | 2017 | Alimentary Pharmacology & Therapeutics |
| Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. | 2017 | Alimentary Pharmacology & Therapeutics |
